<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55275">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01820832</url>
  </required_header>
  <id_info>
    <org_study_id>Calcitriol-MP-1</org_study_id>
    <nct_id>NCT01820832</nct_id>
  </id_info>
  <brief_title>Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD</brief_title>
  <official_title>Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and efficacy of Caltriol on mild proteinuria (&lt;1.0g/d) reduction in CKD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proteinuria is not only a capital sign of kidney disease, but also a marker of chronic
      kidney disease (CKD) progression. Emerging evidence in patients with CKD show that vitamin D
      and its analogs can reduce proteinuria or albuminuria in the presence of
      angiotensin-converting enzyme inhibithion. While some of the studies  reported that vitamin
      D receptor activation has been associated with increased serum creatinine and reduced
      estimated glomerular filtration rates. Therefore, the investigators plan to conduct a
      randomized clinical study to evaluate the efficacy and safety of Calcitriol in the treatment
      of mild proteinuria (&lt;1.0g/d) CKD patients,which has no specific treatment at present.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the percentage change of proteinuia</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients achieving at least a 15% decrease in proteinuria</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>mean change of renal function (serum creatine, cystatin C, eGFR)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>blood pressure</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Calcitriol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>General treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>Calcitriol 0.5 ug/BIW for 24 weeks.</description>
    <arm_group_label>Calcitriol</arm_group_label>
    <other_name>1, 25 - dihydroxy Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18-75 years

          -  clinical diagnosed and/or biopsy-confirmed primary glomerulonephritis

          -  proteinuria 0.15-1.0 g/d in 2 consecutive samples within 4 weeks despite ACE
             inhibitor (ACEI) or angiotensin receptor blocker (ARB) treatment for at least 1 year
             or ACEI/ARB withdrawal because of of drug intolerances (low blood pressure, cough,
             hyperkalemia) for at least 1 month

          -  estimated glomerular filtration rate (eGFR)&gt;60ml/min/1/73m2

          -  corticosteroid and immunosuppressive agents withdrawal for at least 6 months

          -  normal blood pressure

          -  serum intact parathyroid hormone (iPTH) level &gt;20pg/mL

          -  corrected serum calcium level &lt; or = 2.55 mmol/L

          -  serum phosphorus level &lt; or = 1.68 mmol/L

          -  24 hours urinary calcium excretion level &lt; or = 7.5 mmol

          -  not receive treatment of vitamin D or its analogue within 6 months

          -  willigness to give written consent and comply with the study protocol

        Exclusion Criteria:

          -  history of sensitivity or allergy to calcitriol or other vitamin D analogs

          -  pregnancy, lactating women

          -  history of severe coexisting disease such as, but not limited to, chronic liver
             disease, myocardial infarction, cerebrovascular accident, malignant hypertension

          -  history of malignancy

          -  history of extraskeletal calcification, hyperuricemia, gout, kidney stone, gall
             stone, bone diseases

          -  patients receiving drugs contains of calcium

          -  patients receiving  cimetidine, trimethoprim, or other drugs which can increase
             tubular creatinine reabsorption

          -  participation in any other trials within 1 month

          -  history of non-compliance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Chen, M.D. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Huashan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Chen, M.D. PhD</last_name>
    <phone>86-21-52889387</phone>
    <email>chenjing1998@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li You, M.D. PhD</last_name>
    <phone>86-21-52888133</phone>
    <email>youlizzy@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li You, M.D. PhD</last_name>
      <phone>86-21-52888133</phone>
      <email>youlizzy@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 28, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Jing Chen</investigator_full_name>
    <investigator_title>Professor, PhD., MD, Renal Division</investigator_title>
  </responsible_party>
  <keyword>mild proteinuria</keyword>
  <keyword>calcitriol</keyword>
  <keyword>renal function</keyword>
  <keyword>blood pressure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
